Free Trial
→ $5,000 DOGE check? (From Altimetry) (Ad)

ESSA Pharma Q1 2025 Earnings Report

ESSA Pharma logo
$1.72 -0.03 (-1.71%)
As of 02/21/2025 04:00 PM Eastern
Earnings HistoryForecast

ESSA Pharma EPS Results

Actual EPS
-$0.19
Consensus EPS
-$0.18
Beat/Miss
Missed by -$0.01
One Year Ago EPS
N/A

ESSA Pharma Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

ESSA Pharma Announcement Details

Quarter
Q1 2025
Date
2/11/2025
Time
Before Market Opens

Conference Call Resources

ESSA Pharma Earnings Headlines

EPIX Investors Have Opportunity to Lead ESSA Pharma Inc. Securities Fraud Lawsuit
February 22 at 10:26 AM | prnewswire.com
EPIX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that ESSA Pharma Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
February 21 at 4:00 PM | globenewswire.com
$5,000 DOGE check?
Elon Musk's DOGE agenda just took a very surprising turn... Earlier this week, reports emerged that a portion of the savings DOGE makes in Federal cuts could be funneled back to taxpayers. The media was quick to dub it a DOGE Dividend, with claims circulating that we could all receive a $5,000 check in the mail.
February 22, 2025 | Altimetry (Ad)
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 25, 2025 in ESSA Pharma Inc. Lawsuit – EPIX
February 21 at 1:42 PM | globenewswire.com
ESSA Pharma Inc. Class Action: Levi & Korsinsky Reminds ESSA Pharma Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 25, 2025 - EPIX
February 21 at 5:45 AM | prnewswire.com
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages ESSA Pharma Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - EPIX
February 20 at 7:25 PM | globenewswire.com
See More ESSA Pharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like ESSA Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ESSA Pharma and other key companies, straight to your email.

About ESSA Pharma

ESSA Pharma (NASDAQ:EPIX), a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.

View ESSA Pharma Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles